Atomoxetine adhd
Pro Research Analysisby 
Searched over 200M research papers for "atomoxetine adhd"
Consensus Meter
Atomoxetine for ADHD: Mechanism, Efficacy, and Safety
Mechanism of Action: Norepinephrine Reuptake Inhibition
Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. It works by inhibiting the presynaptic norepinephrine transporter (NET), which prevents the reuptake of norepinephrine (NE) throughout the brain. Additionally, it inhibits the reuptake of dopamine in specific brain regions such as the prefrontal cortex (PFC). This unique mechanism differentiates atomoxetine from stimulant medications, which primarily increase dopamine levels.
Clinical Efficacy: Symptom Reduction and Functional Improvement
Children and Adolescents
Several studies have demonstrated the efficacy of atomoxetine in reducing ADHD symptoms in children and adolescents. In a randomized, placebo-controlled study, atomoxetine was found to be superior to placebo in reducing both inattentive and hyperactive/impulsive symptoms. The study also showed improvements in social and family functioning. Another study confirmed that once-daily administration of atomoxetine provided continuous symptom relief throughout the day, including evening and morning hours.
Adults
Atomoxetine has also been shown to be effective in adults with ADHD. In two large, multicenter trials, atomoxetine significantly reduced both inattentive and hyperactive/impulsive symptoms compared to placebo. Additionally, atomoxetine improved response inhibition, likely through noradrenergic augmentation of prefrontal cortex function.
Safety and Tolerability
Atomoxetine is generally well tolerated across different age groups. Common adverse events include decreased appetite, somnolence, and fatigue, but discontinuations due to adverse events are relatively low . The drug's safety profile is comparable to that of methylphenidate, another common ADHD medication.
Dosage Regimen: Optimal Dosing and Administration
Children and Adolescents
The efficacy of atomoxetine increases with dosage up to approximately 1.4 mg/kg, after which it reaches a plateau. A dose of 1.2 mg/kg/day is often recommended as the initial target dose, as it provides a balance between efficacy and tolerability. Atomoxetine can be administered either as a single daily dose or split into two evenly divided doses.
Adults
In adults, atomoxetine is typically administered in doses ranging from 25 to 100 mg daily. The dosing regimen can be adjusted based on individual response and tolerability.
Comorbid Conditions: Anxiety and Alcohol Use Disorders
Anxiety Disorders
Atomoxetine has shown efficacy in treating ADHD symptoms in children with comorbid anxiety disorders. In a double-blind study, atomoxetine significantly reduced both ADHD and anxiety symptoms compared to placebo.
Alcohol Use Disorders
In adults with ADHD and comorbid alcohol use disorders, atomoxetine significantly improved ADHD symptoms. Although it did not significantly affect the time-to-relapse for heavy drinking, it did reduce the cumulative number of heavy drinking days.
Long-term Efficacy: Relapse Prevention
Long-term studies indicate that atomoxetine is effective in preventing relapse in pediatric patients who respond to initial treatment. In a 9-month double-blind study, atomoxetine was superior to placebo in maintaining symptom reduction and improving psychosocial functioning.
Conclusion
Atomoxetine is a well-established, non-stimulant treatment for ADHD that offers significant benefits in symptom reduction and functional improvement across different age groups. Its unique mechanism of action, favorable safety profile, and efficacy in treating comorbid conditions make it a valuable option for managing ADHD.
Sources and full results
Most relevant research papers on this topic